acetyllysine | 1071-49-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: acetyllysine
• 英文别名: N_ε-acetyllysine；6-Acetamido-2-azaniumylhexanoate
• CAS: 1071-49-4
• 化学式: C₈H₁₆N₂O₃
• mdl: MFCD00063940
• 分子量: 188.227
• InChiKey: DTERQYGMUDWYAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  acetyllysine 在 吡啶 、 camphor-10-sulfonic acid 、 乙酸酐 、 二氯磷酸苯酯 作用下， 以 二氯甲烷 为溶剂， 反应 267.0h， 生成 Benzyl 6-Acetamido-2-isocyanohexanoate
  参考文献：
  名称：

  JP2015/42622

  摘要：

  公开号：
• 作为产物：
  描述：

  6-acetamido-2-oxohexanoic acid sodium salt 在 platinum on activated charcoal 氢气 、 sodium cyanoborohydride 、 三氟乙酸 作用下， 以 盐酸 、 甲醇 为溶剂， -78.0~25.0 ℃ 、101.33 kPa 条件下， 生成 acetyllysine
  参考文献：
  名称：

  Kilgore, James L.; Aberhart, D. John, Journal of the Chemical Society. Perkin transactions I, 1991, # 1, p. 79 - 84

  摘要：

  DOI：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• Process for producing dipeptides or dipeptide derivatives
  申请人：Hashimoto Shin-ichi

  公开号：US20050287627A1

  公开（公告）日：2005-12-29

  The present invention provides a process for producing a dipeptide or a dipeptide derivative using a phosphate donor, a substance selected from the group consisting of adenosine-5′-monophosphate, adenosine-5′-diphosphate and adenosine-5′-triphosphate, one or more kinds of amino acids or amino acid derivatives, and as enzyme sources, a protein having polyphosphate kinase activity, or a culture of cells having the ability to produce the protein or a treated matter of the culture, and a protein having the activity to ATP-dependently form the dipeptide or dipeptide derivative from one or more kinds of amino acids or amino acid derivatives, or a culture of cells having the ability to produce the protein or a treated matter of the culture.

  本发明提供了一种利用磷酸供体、从腺苷-5′-单磷酸、腺苷-5′-二磷酸和腺苷-5′-三磷酸组成的一组物质中选择的物质、一种或多种氨基酸或氨基酸衍生物，以及作为酶源的具有多磷酸激酶活性的蛋白质，或者具有产生该蛋白质的能力的细胞培养物，以及具有ATP依赖性形成该二肽或二肽衍生物的活性蛋白质，或者具有产生该蛋白质的能力的细胞培养物或经处理的培养物质的生产二肽或二肽衍生物的过程。
• [EN] HISTONE DEACETYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DESACETYLASE
  申请人：QUEEN MARY & WESTFIELD COLLEGE

  公开号：WO2004046094A1

  公开（公告）日：2004-06-03

  The present invention provides histone deacetylase inhibitors of general formula (I), process for the preparation of such compounds and uses of the compounds in medicine.

  本发明提供了一般式(I)的组蛋白去乙酰化酶抑制剂，以及制备这类化合物的方法和这些化合物在医学上的用途。
• ANTI-ANGIOGENIC COMPOUNDS
  申请人：Bradshaw Curt

  公开号：US20080166364A1

  公开（公告）日：2008-07-10

  The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

  本发明提供了包括与抗体的结合位点连接的AA靶向剂-连接剂共轭物的AA靶向化合物。提供了化合物的各种用途，包括治疗与异常血管生成相关的疾病的方法。
• [EN] INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES<br/>[FR] INHIBITEURS D'ENZYMES D'ACTIVATION DE FACTEUR DE CROISSANCE
  申请人：UNIV WASHINGTON

  公开号：WO2016144654A1

  公开（公告）日：2016-09-15

  The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.

  本发明通常涉及对抑制肝细胞生长因子激活剂、麦曲丝蛋白、赫普星、Xa因子或凝血酶等的化合物有用的化合物。本发明还涉及使用抑制剂化合物的各种方法，包括通过向需要的受试者施用有效量的抑制剂来治疗恶性肿瘤、癌前病变或癌症。